Αποτελέσματα Αναζήτησης
10 Ιουλ 2024 · GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention. The result “provides hope of accelerating efforts to end AIDS”, UNAIDS says, “but only if Gilead ensures that all people who need it can have access to this game-changing ...
4 Ιαν 2023 · Sunlenca (lenacapavir) is a new type of antiretroviral medication for HIV-1 patients who have resistance, intolerance, or safety issues with other drugs. It is the first capsid inhibitor approved by the FDA and is given as oral tablets and subcutaneous injections every six months.
18 Νοε 2021 · Thousands of people with HIV will now be offered a new long-acting injection to manage their condition if they would prefer to stop taking daily pills. Charities have welcomed the approval of the...
23 Δεκ 2021 · The Food and Drug Administration has approved the first injectable medication for HIV prevention. Health advocates say it could be a game changer in protecting people against AIDS
27 Ιαν 2021 · Cabenuva and Vocabria are the first FDA-approved injectable, complete regimen for HIV-1 infected adults that is administered once a month. They are indicated as a replacement therapy for patients who are virologically suppressed on a stable antiretroviral regimen.
23 Δεκ 2021 · Apretude, a new drug approved by the FDA this week, is an injection that has proven to be significantly more effective at reducing the risk of sexually-acquired HIV.
10 Ιαν 2023 · The FDA has approved Gilead Science’s first-in-class capsid inhibitor lenacapavir, providing a new treatment option for people with multidrug-resistant HIV.
